<DOC>
	<DOCNO>NCT00884767</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient receive oxaliplatin cancer may help doctor learn change occur DNA identify biomarkers related neurotoxicity . PURPOSE : This phase II trial study biomarkers predict neurotoxicity patient colorectal cancer receive oxaliplatin .</brief_summary>
	<brief_title>Biomarkers Predicting Neurotoxicity Patients With Colorectal Cancer Receiving Oxaliplatin</brief_title>
	<detailed_description>OBJECTIVES : Primary - Correlate predictive genetic , proteomic , and/or neurotrophic marker neurological manifestation relate administration oxaliplatin patient colorectal carcinoma . Secondary - Differentiate risk factor predictive acute chronic neurotoxicity . - Establish possible relationship acute chronic neurotoxicity . OUTLINE : This multicenter study . Patients receive oxaliplatin every 2 week part FOLFOX chemotherapy regimen . Blood sample collect 15 day prior begin chemotherapy , prior course chemotherapy , 1 month completion chemotherapy pharmacogenetic laboratory biological study . Patients chronic neurotoxicity undergo additional blood sample collection 3 , 6 , 9 , 12 month completion chemotherapy . Samples analyze detection gene variant involve oxalate fluorouracil metabolic pathway ; neurotrophic factor ; proteomic analysis plasma proteins peptide ; biological testing neurotoxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Requires treatment oxaliplatin ( part FOLFOX regimen ) No brain metastases symptomatic meningitis PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 3 month ANC ≥ 1 x 10^9/L Platelet count ≥ 100 x 10^9/L Total bilirubin ≤ 2 time upper limit normal ( ULN ) Transaminases ≤ 3 time ULN Alkaline phosphatase ≤ 5 time ULN Not pregnant nursing Fertile patient must use effective contraception No prior concurrent clinical neuropathy ( regardless etiology ) No dihydropyrimidine dehydrogenase deficiency No psychiatric illness would preclude comprehension study inform consent No severe illness may worsen treatment , include unstable cardiac disease , myocardial infarction within past 6 month , active uncontrolled infection No psychological , social , familial , geographical reason would preclude study followup Other cancer within past 5 year allow provide treatment include platinum derivative taxanes PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior chemotherapy allow ( except platinum derivative taxanes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>